
Paul Sekhri
QuietNamed in filings at Aditum BioOn the current fund
- Board seats filed
- 11

Named in filings at Aditum BioOn the current fund
all filings on record
last 24 months
from a verified or cited source
| vTv Therapeutics | Biotech & pharma | February 2024 | Novalis Lifesciences Investments, Rogue, Samsara Biocapital |
| Axcella Health | Biotech & pharma | September 2022 | None on file |
| BiomX | Aerospace & defense | October 2021 | None on file |
| eGenesis | Biotech & pharma | November 2019 | Alta Partners, ARCH Venture Partners |
| ALPINE IMMUNE SCIENCES | Biotech & pharma | January 2019 | Frazier Life Sciences |
| COMPUGEN | Biotech & pharma | October 2018 | None on file |
| LikeMinds, Inc./DE | Enterprise software | September 2018 | None on file |
| Enumeral Biomedical Holdings | Biotech & pharma | July 2016 | None on file |
| Petra Pharma | Biotech & pharma | December 2015 | ARCH Venture Partners |
| LYCERA | Biotech & pharma | June 2015 | ARCH Venture Partners |
| PATIENTSAFE SOLUTIONS | Digital health | December 2013 | Brewer Lane Ventures, General Catalyst, KSN |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Categories of companies where filings name Paul Sekhri on the board, based on 11 filed seats with a verified or cited source.